Not provided
Not provided
| ID | Type | Description | Link |
|---|---|---|---|
| 2021-A02134-37 | Other Identifier | ID RCB |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Bone and joint infections (BJI) are most often bacterial infections that can occur after surgery or de novo. They are rarely fatal in the short term, but are associated with significant morbidity, impaired quality of life and significant costs. Treatment of BJI is based on antibiotic therapy, often combined with surgery. Antibiotic therapy, at high doses, lasts a minimum of 6 weeks. It can be responsible for severe adverse effects. These characteristics (prolonged duration, multiple daily doses, and adverse effects) are known to negatively affect treatment adherence in general.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Tolerance and adherence to oral antibiotics in patients managed for BJI | Patients having a BJI treated by surgery and taking at least one oral antibiotic after the surgery |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Tolerance and adherence to oral antibiotics in patients managed for BJI | Other | Adherence will be measured 6 weeks (S6) and 3 months (M3) after the surgery. Tolerance will be mesured at baseline, and at 6 weeks (S6) and 3 months (M3) after the surgery. The compliance data collected will be compared by two methods (electronic pill dispensers and questionnaire). Patients will respond to a questionnaire about the tolerance of intraveinous antibiotics (between surgery and baseline) and oral antibiotics at baseline, and during the consultation at S6 and M3. Responses to the compliance questionnaire will be collected during a telephone interview by a member of the Croix-Rousse pharmacy at S6 and M3. The pill organizer data from S6 and M3 will be transferred to the software by a nurse. |
| Measure | Description | Time Frame |
|---|---|---|
| Percentage of doses taken at 6 weeks | Ratio of the number of doses taken over the theoretical number of doses to be taken over the period | At 6 weeks after surgery |
| Percentage of doses taken at 3 months | Ratio of the number of doses taken over the theoretical number of doses to be taken over the period | at 3 months after surgery |
Not provided
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
patients having a BJI treated by at least one oral antibiotic after a surgery
| Name | Role | Phone | Extension | |
|---|---|---|---|---|
| Tristan FERRY, MD, PHD | Contact | 4 26 73 29 38 | +33 | tristan.ferry@chu-lyon.fr |
| Name | Affiliation | Role |
|---|---|---|
| Valérie MIRABET | Hospices Civils de Lyon | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Hospices Civils de Lyon | Recruiting | Lyon | 69004 | France |
Not provided
| ID | Term |
|---|---|
| D064420 | Drug-Related Side Effects and Adverse Reactions |
| D000074822 | Treatment Adherence and Compliance |
| ID | Term |
|---|---|
| D064419 | Chemically-Induced Disorders |
| D015438 | Health Behavior |
| D001519 | Behavior |
Not provided
Not provided
| ID | Term |
|---|---|
| D004361 | Drug Tolerance |
| ID | Term |
|---|---|
| D000069437 | Pharmacological Phenomena |
| D002620 | Pharmacological and Toxicological Phenomena |
| D010829 | Physiological Phenomena |
Not provided
Not provided
Not provided
Not provided
Not provided
|